Kendall Capital Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $784K | Sell |
3,976
-41
| -1% | -$7.91K | 0.16% | 131 |
|
|
2025
Q4 | $739K | Hold |
4,017
| – | – | 0.15% | 136 |
|
|
2025
Q3 | $616K | Buy |
4,017
+13
| +0.3% | +$1.97K | 0.14% | 141 |
|
|
2025
Q2 | $560K | Hold |
4,004
| – | – | 0.15% | 140 |
|
|
2025
Q1 | $589K | Buy |
4,004
+2,073
| +107% | +$300K | 0.17% | 137 |
|
|
2024
Q4 | $253K | Sell |
1,931
-12
| -0.6% | -$1.68K | 0.07% | 194 |
|
|
2024
Q3 | $303K | Sell |
1,943
-13
| -0.7% | -$2.1K | 0.09% | 183 |
|
|
2024
Q2 | $305K | Sell |
1,956
-25
| -1% | -$3.76K | 0.1% | 172 |
|
|
2024
Q1 | $268K | Buy |
1,981
+310
| +19% | +$41K | 0.09% | 185 |
|
|
2023
Q4 | $225K | Sell |
1,671
-12
| -0.7% | -$1.56K | 0.09% | 193 |
|
|
2023
Q3 | $228K | Hold |
1,683
| – | – | 0.1% | 178 |
|
|
2023
Q2 | $241K | Sell |
1,683
-138
| -8% | -$20.3K | 0.11% | 176 |
|
|
2023
Q1 | $253K | Hold |
1,821
| – | – | 0.12% | 161 |
|
|
2022
Q4 | $247K | Sell |
1,821
-25
| -1% | -$3.13K | 0.12% | 158 |
|
|
2022
Q3 | $202K | Sell |
1,846
-50
| -3% | -$6.34K | 0.12% | 164 |
|
|
2022
Q2 | $250K | Hold |
1,896
| – | – | 0.14% | 149 |
|
|
2022
Q1 | $251K | Sell |
1,896
-54
| -3% | -$6.48K | 0.12% | 155 |
|
|
2021
Q4 | $227K | Sell |
1,950
-46
| -2% | -$5.41K | 0.11% | 156 |
|
|
2021
Q3 | $240K | Buy |
1,996
+53
| +3% | +$6.17K | 0.13% | 144 |
|
|
2021
Q2 | $233K | Buy |
+1,943
| New | +$213K | 0.13% | 140 |
|
|
2020
Q4 | – | Sell |
-1,943
| Closed | -$213K | – | 127 |
|
|
2020
Q3 | $213K | Sell |
1,943
-625
| -24% | -$69.5K | 0.19% | 115 |
|
|
2020
Q2 | $272K | Hold |
2,568
| – | – | 0.26% | 97 |
|
|
2020
Q1 | $229K | Hold |
2,568
| – | – | 0.26% | 92 |
|
|
2019
Q4 | $256K | Sell |
2,568
-110
| -4% | -$10.4K | 0.2% | 105 |
|
|
2019
Q3 | $239K | Sell |
2,678
-312
| -10% | -$27.1K | 0.21% | 104 |
|
|
2019
Q2 | $247K | Sell |
2,990
-143
| -5% | -$11.2K | 0.22% | 105 |
|
|
2019
Q1 | $253K | Sell |
3,133
-175
| -5% | -$13.8K | 0.24% | 97 |
|
|
2018
Q4 | $251K | Sell |
3,308
-225
| -6% | -$17.6K | 0.26% | 92 |
|
|
2018
Q3 | $280K | Sell |
3,533
-1,800
| -34% | -$136K | 0.24% | 96 |
|
|
2018
Q2 | $374K | Sell |
5,333
-2,575
| -33% | -$185K | 0.33% | 82 |
|
|
2018
Q1 | $553K | Sell |
7,908
-100
| -1% | -$6.93K | 0.48% | 66 |
|
|
2017
Q4 | $556K | Buy |
+8,008
| New | +$540K | 0.49% | 64 |
|
Other funds holding AZN
IA
VCM
VAM
Kendall Capital Management's AZN Position: Q1 2026 in Review
Kendall Capital Management reduced its AstraZeneca (AZN) stake by 1% in Q1 2026, selling an estimated $7.91K and leaving 3,976 shares worth $784K. The position accounts for 0.16% of the portfolio, ranked #131.
Kendall Capital Management first reported a position in AZN in Q4 2017 and has held it in 32 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Kendall Capital Management held 3,976 shares of AstraZeneca worth $784K as of Q1 2026.
- Kendall Capital Management sold 41 AstraZeneca shares in Q1 2026, an estimated $7.91K.
- AstraZeneca made up 0.16% of Kendall Capital Management's portfolio in Q1 2026, its #131 holding.
- Kendall Capital Management first reported a position in AstraZeneca in Q4 2017 and has held it in 32 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Kendall Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.